Coherus Biosciences Inc (CHRS) concluded trading on Thursday at a closing price of $0.95, with 3.48 million shares of worth about $3.3 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -9.00% during that period and on March 20, 2025 the price saw a gain of about 4.31%. Currently the company’s common shares owned by public are about 115.89M shares, out of which, 111.28M shares are available for trading.
Stock saw a price change of 6.27% in past 5 days and over the past one month there was a price change of -13.96%. Year-to-date (YTD), CHRS shares are showing a performance of -31.42% which decreased to -57.37% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.66 but also hit the highest price of $2.64 during that period. The average intraday trading volume for Coherus Biosciences Inc shares is 1.99 million. The stock is currently trading -6.98% below its 20-day simple moving average (SMA20), while that difference is down -18.45% for SMA50 and it goes to -25.67% lower than SMA200.
Coherus Biosciences Inc (NASDAQ: CHRS) currently have 115.89M outstanding shares and institutions hold larger chunk of about 54.15% of that.
The stock has a current market capitalization of $109.68M and its 3Y-monthly beta is at 0.96. PE ratio of stock for trailing 12 months is 5.43, while it has posted earnings per share of $0.17 in the same period. It has Quick Ratio of 1.41. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CHRS, volatility over the week remained 7.98% while standing at 9.35% over the month.
Stock’s fiscal year EPS is expected to drop by -81.14% while it is estimated to decrease by -2214.00% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by UBS on August 16, 2024 offering a Neutral rating for the stock and assigned a target price range of between $4 and $1.50 to it. Coverage by Robert W. Baird stated Coherus Biosciences Inc (CHRS) stock as an Outperform in their note to investors on November 17, 2023, suggesting a price target of $11 for the stock. On November 08, 2023, Maxim Group Downgrade their recommendations, while on July 24, 2023, Citigroup Initiated their ratings for the stock with a price target of $12. Stock get a Buy rating from Truist on May 01, 2023.
